Pfizer just closed on its $43 billion takeover of Seagen, a biotech focused on cancer treatments.
Today, not even two new acquisitions can give its stock a booster shot. It’s lost 55% of its value from the all-time high it hit two years ago when its Covid therapies Comirnaty and Paxlovid ruled the pandemic-stricken world.
Pharmaceutical giant Pfizer (NYSE: PFE) is trading at levels it hasn’t seen in over a decade.
